An update from Tonix Pharma ( (TNXP) ) is now available.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tonix Pharmaceuticals has partnered with the Kenya Medical Research Institute to launch a Phase I clinical trial for its TNX-801 vaccine aimed at preventing mpox and smallpox. This collaboration will see Tonix sponsoring the trial while KEMRI leads its execution, marking a significant step in vaccine development and regulatory approval processes. Investors should note that this announcement includes forward-looking statements about the company’s future operations and market potential.
Learn more about TNXP stock on TipRanks’ Stock Analysis page.
